FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891576771> ?p ?o ?g. }

• W2891576771 endingPage "1416" @default.
• W2891576771 startingPage "1404" @default.
• W2891576771 abstract "Background In the SPARTAN trial, addition of apalutamide to androgen deprivation therapy, as compared with placebo plus androgen deprivation therapy, significantly improved metastasis-free survival in men with non-metastatic castration-resistant prostate cancer who were at high risk for development of metastases. We aimed to investigate the effects of apalutamide versus placebo added to androgen deprivation therapy on health-related quality of life (HRQOL). Methods SPARTAN is a multicentre, international, randomised, phase 3 trial. Participants were aged 18 years or older, with non-metastatic castration-resistant prostate cancer, a prostate-specific antigen doubling time of 10 months or less, and a prostate-specific antigen concentration of 2 ng/mL or more in serum. Patients were randomly assigned (2:1) to 240 mg oral apalutamide per day plus androgen deprivation therapy, or matched oral placebo plus androgen deprivation therapy, using an interactive voice randomisation system. Permuted block randomisation was used according to the three baseline stratification factors: prostate-specific antigen doubling time (>6 months vs ≤6 months), use of bone-sparing drugs (yes vs no), and presence of local-regional nodal disease (N0 vs N1). Each treatment cycle was 28 days. The primary endpoint was metastasis-free survival. The trial was unblinded in July, 2017. In this prespecified exploratory analysis we assessed HRQOL using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) and EQ-5D-3L questionnaires, which we collected at baseline, day 1 of cycle 1 (before dose), day 1 of treatment cycles 1–6, day 1 of every two cycles from cycles 7 to 13, and day 1 of every four cycles thereafter. This study is registered with ClinicalTrials.gov, number NCT01946204. Findings Between Oct 14, 2013, and Dec 15, 2016, we randomly assigned 1207 patients to receive apalutamide (n=806) or placebo (n=401). The clinical cutoff date, as for the primary analysis, was May 19, 2017. Median follow-up for overall survival was 20·3 months (IQR 14·8–26·6). FACT-P total and subscale scores were associated with a preservation of HRQOL from baseline to cycle 29 in the apalutamide group; there were similar results for EQ-5D-3L. At baseline, the mean for FACT-P total score in both the apalutamide and placebo groups were consistent with the FACT-P general population norm for US adult men. Group mean patient-reported outcome scores over time show that HRQOL was maintained from baseline after initiation of apalutamide treatment and was similar over time among patients receiving apalutamide versus placebo. Least-squares mean change from baseline shows that HRQOL deterioration was more apparent in the placebo group. Interpretation In asymptomatic men with high-risk non-metastatic castration-resistant prostate cancer, HRQOL was maintained after initiation of apalutamide treatment. Considered with findings from SPARTAN, patients who received apalutamide had longer metastasis-free survival and longer time to symptomatic progression than did those who received placebo, while preserving HRQOL. Funding Janssen Research & Development. In the SPARTAN trial, addition of apalutamide to androgen deprivation therapy, as compared with placebo plus androgen deprivation therapy, significantly improved metastasis-free survival in men with non-metastatic castration-resistant prostate cancer who were at high risk for development of metastases. We aimed to investigate the effects of apalutamide versus placebo added to androgen deprivation therapy on health-related quality of life (HRQOL). SPARTAN is a multicentre, international, randomised, phase 3 trial. Participants were aged 18 years or older, with non-metastatic castration-resistant prostate cancer, a prostate-specific antigen doubling time of 10 months or less, and a prostate-specific antigen concentration of 2 ng/mL or more in serum. Patients were randomly assigned (2:1) to 240 mg oral apalutamide per day plus androgen deprivation therapy, or matched oral placebo plus androgen deprivation therapy, using an interactive voice randomisation system. Permuted block randomisation was used according to the three baseline stratification factors: prostate-specific antigen doubling time (>6 months vs ≤6 months), use of bone-sparing drugs (yes vs no), and presence of local-regional nodal disease (N0 vs N1). Each treatment cycle was 28 days. The primary endpoint was metastasis-free survival. The trial was unblinded in July, 2017. In this prespecified exploratory analysis we assessed HRQOL using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) and EQ-5D-3L questionnaires, which we collected at baseline, day 1 of cycle 1 (before dose), day 1 of treatment cycles 1–6, day 1 of every two cycles from cycles 7 to 13, and day 1 of every four cycles thereafter. This study is registered with ClinicalTrials.gov, number NCT01946204. Between Oct 14, 2013, and Dec 15, 2016, we randomly assigned 1207 patients to receive apalutamide (n=806) or placebo (n=401). The clinical cutoff date, as for the primary analysis, was May 19, 2017. Median follow-up for overall survival was 20·3 months (IQR 14·8–26·6). FACT-P total and subscale scores were associated with a preservation of HRQOL from baseline to cycle 29 in the apalutamide group; there were similar results for EQ-5D-3L. At baseline, the mean for FACT-P total score in both the apalutamide and placebo groups were consistent with the FACT-P general population norm for US adult men. Group mean patient-reported outcome scores over time show that HRQOL was maintained from baseline after initiation of apalutamide treatment and was similar over time among patients receiving apalutamide versus placebo. Least-squares mean change from baseline shows that HRQOL deterioration was more apparent in the placebo group. In asymptomatic men with high-risk non-metastatic castration-resistant prostate cancer, HRQOL was maintained after initiation of apalutamide treatment. Considered with findings from SPARTAN, patients who received apalutamide had longer metastasis-free survival and longer time to symptomatic progression than did those who received placebo, while preserving HRQOL." @default.
• W2891576771 created "2018-09-27" @default.
• W2891576771 creator A5002270524 @default.
• W2891576771 creator A5007578304 @default.
• W2891576771 creator A5017925159 @default.
• W2891576771 creator A5020669411 @default.
• W2891576771 creator A5039180386 @default.
• W2891576771 creator A5039344852 @default.
• W2891576771 creator A5039922522 @default.
• W2891576771 creator A5043791596 @default.
• W2891576771 creator A5047019507 @default.
• W2891576771 creator A5053749991 @default.
• W2891576771 creator A5061759413 @default.
• W2891576771 creator A5075033014 @default.
• W2891576771 creator A5077243123 @default.
• W2891576771 creator A5084322798 @default.
• W2891576771 creator A5091400921 @default.
• W2891576771 date "2018-10-01" @default.
• W2891576771 modified "2023-09-23" @default.
• W2891576771 title "Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial" @default.
• W2891576771 cites W1486562387 @default.
• W2891576771 cites W1999658754 @default.
• W2891576771 cites W2004909463 @default.
• W2891576771 cites W2019607817 @default.
• W2891576771 cites W2019970875 @default.
• W2891576771 cites W2029087193 @default.
• W2891576771 cites W2051632397 @default.
• W2891576771 cites W2084637523 @default.
• W2891576771 cites W2099219018 @default.
• W2891576771 cites W2101134619 @default.
• W2891576771 cites W2120377396 @default.
• W2891576771 cites W2127307826 @default.
• W2891576771 cites W2137490386 @default.
• W2891576771 cites W2140525590 @default.
• W2891576771 cites W2145043534 @default.
• W2891576771 cites W2148643283 @default.
• W2891576771 cites W2166918329 @default.
• W2891576771 cites W2172161665 @default.
• W2891576771 cites W2195040438 @default.
• W2891576771 cites W2278392405 @default.
• W2891576771 cites W2473786944 @default.
• W2891576771 cites W2495059596 @default.
• W2891576771 cites W2562421418 @default.
• W2891576771 cites W2590151349 @default.
• W2891576771 cites W2605070587 @default.
• W2891576771 cites W2765843352 @default.
• W2891576771 cites W2769746786 @default.
• W2891576771 cites W2792086148 @default.
• W2891576771 doi "https://doi.org/10.1016/s1470-2045(18)30456-x" @default.
• W2891576771 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30213449" @default.
• W2891576771 hasPublicationYear "2018" @default.
• W2891576771 type Work @default.
• W2891576771 sameAs 2891576771 @default.
• W2891576771 citedByCount "100" @default.
• W2891576771 countsByYear W28915767712018 @default.
• W2891576771 countsByYear W28915767712019 @default.
• W2891576771 countsByYear W28915767712020 @default.
• W2891576771 countsByYear W28915767712021 @default.
• W2891576771 countsByYear W28915767712022 @default.
• W2891576771 countsByYear W28915767712023 @default.
• W2891576771 crossrefType "journal-article" @default.
• W2891576771 hasAuthorship W2891576771A5002270524 @default.
• W2891576771 hasAuthorship W2891576771A5007578304 @default.
• W2891576771 hasAuthorship W2891576771A5017925159 @default.
• W2891576771 hasAuthorship W2891576771A5020669411 @default.
• W2891576771 hasAuthorship W2891576771A5039180386 @default.
• W2891576771 hasAuthorship W2891576771A5039344852 @default.
• W2891576771 hasAuthorship W2891576771A5039922522 @default.
• W2891576771 hasAuthorship W2891576771A5043791596 @default.
• W2891576771 hasAuthorship W2891576771A5047019507 @default.
• W2891576771 hasAuthorship W2891576771A5053749991 @default.
• W2891576771 hasAuthorship W2891576771A5061759413 @default.
• W2891576771 hasAuthorship W2891576771A5075033014 @default.
• W2891576771 hasAuthorship W2891576771A5077243123 @default.
• W2891576771 hasAuthorship W2891576771A5084322798 @default.
• W2891576771 hasAuthorship W2891576771A5091400921 @default.
• W2891576771 hasBestOaLocation W28915767712 @default.
• W2891576771 hasConcept C121608353 @default.
• W2891576771 hasConcept C126322002 @default.
• W2891576771 hasConcept C126894567 @default.
• W2891576771 hasConcept C142724271 @default.
• W2891576771 hasConcept C143998085 @default.
• W2891576771 hasConcept C168563851 @default.
• W2891576771 hasConcept C203092338 @default.
• W2891576771 hasConcept C204787440 @default.
• W2891576771 hasConcept C27081682 @default.
• W2891576771 hasConcept C2777899217 @default.
• W2891576771 hasConcept C2780192828 @default.
• W2891576771 hasConcept C2781406297 @default.
• W2891576771 hasConcept C71924100 @default.
• W2891576771 hasConceptScore W2891576771C121608353 @default.
• W2891576771 hasConceptScore W2891576771C126322002 @default.
• W2891576771 hasConceptScore W2891576771C126894567 @default.
• W2891576771 hasConceptScore W2891576771C142724271 @default.
• W2891576771 hasConceptScore W2891576771C143998085 @default.
• W2891576771 hasConceptScore W2891576771C168563851 @default.
• W2891576771 hasConceptScore W2891576771C203092338 @default.
• W2891576771 hasConceptScore W2891576771C204787440 @default.

• next